Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H1 2018

Publisher Name :
Date: 27-Mar-2018
No. of pages: 57

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H1 2018

Summary

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 4 and 8 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Bleeding And Clotting Disorders, Thrombosis, Hemophilia C (Factor XI Deficiency), Sepsis, Venous Thromboembolism, Acute Ischemic Stroke, Arterial Thrombosis, Hemorrhagic Fever, Ischemic Stroke, Stroke and Venous (Vein) Thrombosis.

The latest report Coagulation Factor XI - Pipeline Review, H1 2018, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Ionis Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Sumitomo Dainippon Pharma Co Ltd
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
AB-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-262084 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-962212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-130787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-7041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXILRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAA-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
Featured News & Press Releases
Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017
Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals to Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
Oct 29, 2012: Isis Pharma Initiates Phase II Study of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Feb 02, 2011: Isis Initiates Phase I Clinical Trial of ISIS-FXIRx To Treat Clotting Disorders
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Bio Products Laboratory Ltd, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Collagenase Industry Market Research 2019
    Published: 22-Mar-2019        Price: US 2600 Onwards        Pages: 158
    In this report, we analyze the Collagenase industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a predic......
  • Global Collagenase Market Insights, Forecast to 2025
    Published: 22-Mar-2019        Price: US 3900 Onwards        Pages: 119
    Collagenase, obtained from Clostridium histolyticum, is an enzyme used for tissue dissociation in vitro and thus for isolation of many different types of cells. These isolated cells are then used for numerous clinical and research applications. The technical barriers of collagenase are high, and the collagenase production concentrated large companies including Nordmark Arzneimittel, Worthington Biochemical, Roche, Thermofisher, Qiaoyuan and others. They are mainly located in USA, Germany,......
  • Global Industrial Enzymes Market Insights, Forecast to 2025
    Published: 22-Mar-2019        Price: US 3900 Onwards        Pages: 118
    Enzymes are protein molecules functioning as specialized catalysts for chemical reactions. They have contributed greatly to the traditional and modern chemical industry by improving existing processes. Enzymes are natural catalysts. They are produced by living organisms to increase the rate of an immense and diverse set of chemical reactions required for life. They are involved in all processes essential for life such as DNA replication and transcription, protein synthesis, metabolism and signal......
  • Global mTOR Inhibitors Market Research Report 2019
    Published: 20-Mar-2019        Price: US 2900 Onwards        Pages: 98
    mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR). Mammalian target of rapamycin (mTOR) inhibitors block the activity of the mammalian target of rapamycin. Mammalian target of rapamycin is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. In certain cancers the mTOR pathway is more active. The global mTOR Inhibitors market is valued at xx million US$ in 2018 is expected to reach xx millio......
  • Global DNA Polymerase Market Research Report 2019
    Published: 19-Mar-2019        Price: US 2900 Onwards        Pages: 99
    DNA polymerases are enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two identical DNA strands from one original DNA molecule. DNA polymerases are used for the copy of DNA molecules in test tubes during polymerase chain reaction (PCR). There are two types of DNA polymerase viz. Prokaryotic DNA Polymerase and Eukaryotic DNA Polymerase. Eukaryotic DNA polymerase is the ......
  • Global Tyrosine Kinase JAK Inhibitors Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 15-Mar-2019        Price: US 3480 Onwards        Pages: 118
    Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attrac......
  • Alcohol Dehydrogenase Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 12-Mar-2019        Price: US 3000 Onwards        Pages: 147
    Alcohol Dehydrogenase Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Alcohol Dehydrogenase industry with a focus on the Chinese market. The report provides key statistics on the market status of the Alcohol Dehydrogenase manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese ......
  • Global Restriction Endonucleases Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 12-Mar-2019        Price: US 3480 Onwards        Pages: 123
    Restriction Endonuclease is an enzyme that cuts DNA at or near specific recognition nucleotide sequences known as restriction sites. They are the enzymes that are found in the bacteria and are harvested from them for their use in research and commercial aspects. Restriction enzymes are commonly classified into four types, which differ in their structure and whether they cut their DNA substrate at their recognition site, or if the recognition and cleavage sites are separate from one another.......
  • Global Catalase Market Insights, Forecast to 2025
    Published: 11-Mar-2019        Price: US 3900 Onwards        Pages: 113
    Catalase is a common enzyme found in nearly all living organisms exposed to oxygen (such as bacteria, plants, and animals).It catalyzes the decomposition of hydrogen peroxide to water and oxygen. In application, Catalase downstream is wide and recently Catalase has acquired increasing significance in various fields of Textile Industry, Food and Beverage, Environmental Protection and Electronics and others. Globally, the Catalase market is mainly driven by growing demand for Textile Indust......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs